

04 June 2021

Clyde Munro reaches milestone

[Synova](#) is excited to announce that Clyde Munro Dental Group, the largest dental group in Scotland, has acquired Mearns Dental Practices, consisting of Mearns Cross and Crookfur Dental practice and in doing so has reached the milestone of completing over 50 practice acquisitions. The Group has continued its impressive expansion in these challenging times and now looks after the oral care of more than 430,000 patients across Scotland.

Synova initially invested in Clyde Munro in 2015 when the Group had seven practices clustered around Glasgow. Since then, the Business has expanded more than seven-fold to become the leading Group in Scotland with an excellent reputation with patients and dental associates, a truly national footprint, and offering the full range of NHS, private and specialist referral services. The Group has also benefitted from investment in market-leading systems and technology, allowing for seamless integration of new practices into the Group and enabling Clyde Munro's clinicians to offer the latest treatments and techniques to their patients.

The Group continues to grow rapidly with a strong pipeline of future acquisitions expected to complete in the coming months, combined with organic growth across the estate.

Tim Ashlin, Partner at Synova, commented: *"It has been a pleasure supporting the Clyde Munro team on their journey to this point and it is wonderful to be able to congratulate them on reaching this milestone of over 50 practices spanning across Scotland. We remain very excited about the future growth opportunities for the Business, which retains an excellent pipeline of future acquisitions, and I look forward to congratulating the team again when they reach the next milestone soon!"* **ENDS**

NOTES:

1. **Synova** is recognised across the industry as one of Europe's most innovative growth investors, investing in companies typically valued between £30m and £150m. We invest across a handful of core sectors, including **Technology, Financial Services, Business Services, and Health & Education**, where we have deep investment and operational expertise
2. Synova has generated industry-leading returns, which has been reflected in being awarded **UK Private Equity House of the Year** four times in the past seven years and has been listed as one of the **Most Consistent Top Performing Buyout Fund Managers** globally by Preqin. We are currently investing our fourth generation fund, raised in 2019
3. Synova has completed a number of new investments and successful exits across the **Health** sector with the sales of **4Ways** to ECI Partners (6.0x invested capital) and **Kinapse** to HgCapital (16.1x invested capital); and investments in **Charnwood Molecular** (drug discovery services), **Preventx** (online-led sexual health testing and diagnostics), **Clyde Munro** (Scottish dental consolidation platform) and **Oakland Care** (premium residential elderly care)

CONTACT:

Tim Ashlin, Partner, Tel: +44 (0)20 3475 7668

synova.pe

UK 55 Wells Street, London W1T 3PT

US 445 Park Avenue, New York, NY10022

Synova Capital LLP | Synova Capital is authorised and regulated in the UK by the Financial Conduct Authority. Registered in England No. OC329299